2O9A Stock Overview
Develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Renalytix Plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.65 |
52 Week High | UK£3.52 |
52 Week Low | UK£0.22 |
Beta | 1.98 |
11 Month Change | 0% |
3 Month Change | -7.14% |
1 Year Change | -65.43% |
33 Year Change | -97.48% |
5 Year Change | n/a |
Change since IPO | -95.00% |
Recent News & Updates
Recent updates
Shareholder Returns
2O9A | DE Healthcare Services | DE Market | |
---|---|---|---|
7D | 0% | -1.9% | 0.09% |
1Y | -65.4% | -24.8% | 3.1% |
Return vs Industry: 2O9A underperformed the German Healthcare Services industry which returned -25.6% over the past year.
Return vs Market: 2O9A underperformed the German Market which returned 4.2% over the past year.
Price Volatility
2O9A volatility | |
---|---|
2O9A Average Weekly Movement | n/a |
Healthcare Services Industry Average Movement | 4.0% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.7% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 2O9A's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 2O9A's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2018 | 102 | James McCullough | renalytix.com |
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Renalytix Plc Fundamentals Summary
2O9A fundamental statistics | |
---|---|
Market cap | €41.49m |
Earnings (TTM) | -€34.48m |
Revenue (TTM) | €2.04m |
20.3x
P/S Ratio-1.2x
P/E RatioIs 2O9A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2O9A income statement (TTM) | |
---|---|
Revenue | US$2.22m |
Cost of Revenue | US$2.26m |
Gross Profit | -US$35.00k |
Other Expenses | US$37.45m |
Earnings | -US$37.49m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.24 |
Gross Margin | -1.58% |
Net Profit Margin | -1,687.80% |
Debt/Equity Ratio | -84.1% |
How did 2O9A perform over the long term?
See historical performance and comparison